Iranian Journal of Immunology

Antitetanus Toxoid Antibody Titer of Chronic Hemodialysis Patients in Iran

Document Type : Original Article

Authors

Mohammad Mahdi Sagheb 1
Sharareh Sajjadi 1
Golmehr Sajjady 2

1 Department of Internal Medicine, Shiraz University of Medical Science, Shiraz, Iran

2 Dundee University Medical school, Scotland, UK

https://doi.org/10.22034/iji.2008.17099
Abstract
Background: Patients with end stage renal disease have higher incidence of infection dis-eases that is thought to be related to impaired immune system.
Objective: To determine the antitetanus IgG antibody level in Iranian hemodialysis patients with end stage renal disease and to find its association with sex, age, blood hemoglobin, serum albumin, dura-tion of dialysis, time of dialysis per week, dialysis adequacy, erythropoietin, or iron sup-plementation, body mass index (BMI) and underlying renal disorder.
Methods: We con-ducted a cross sectional study on a total of 108 Iranian hemodialysis patients with end stage renal disorder, and 36 healthy individuals in the control group matched with the pa-tient group. The patients and controls did not receive any antitetanus vaccine or immu-noglobulins a year prior to the investigation. The serum antitetanus IgG antibody levels were measured by an ELISA method.
Results: We found 74.3% of patients to have un-protected antitetanus IgG antibody level compared with 52.8% of the control group. Ex-cept hemodialysis duration, none of the contributing factors seemed to affect immunity.
Conclusion: We conclude that in our study, there is a significant difference in the an-titetanus IgG antibody level between hemodialysis patients and the control group and also in the chronic hemodialysis patients.

Keywords

Antitetanus IgG
hemodialysis
chronic renal failure
Iranian Journal of Immunology
Volume 5, Issue 1
Winter 2008
Pages 45-50

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us